Parkinson’s Disease and Parkinsonism
Abstract
Parkinson’s disease (PD), or paralysis agitans is a common neurodegenerative and heterogeneous disorder. Parkinson’s symptoms include bradykinesia, rigidity and tremor. PD is pathologically characterized by the loss of dopaminergic neurons of the substantia nigra. Treatment involves pharmacologic and nonpharmacologic approaches.
References
- Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the “common” neurologic disorders? Neurology 2007;68(5):326-37. doi:10.1212/01.wnl.0000252807.38124.a3
- Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson’s disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord 2017;32(9):1264-310. doi:10.1002/mds.27115
- Jankovic J. Parkinson’s disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79(4):368-76. doi:10.1136/jnnp.2007.131045
- Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 2015;30(12):1591-601. doi:10.1002/mds.26424
- Dextera DT, Jenner P. Parkinson disease: From pathology to molecular disease mechanisms. Free Radic Biol Med 2013;62:132-44. doi:10.1016/j.freeradbiomed.2013.01.018
- Ray Dorsey E, Elbaz A, et al. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018;17(11):939-53. doi:10.1016/S1474-4422(18)30295-3
- Dorsey ER, Bloem BR. The Parkinson pandemic – A call to action. JAMA Neurol 2018;75(1):9-10. doi:10.1001/jamaneurol.2017.3299
- Jankovic J, Tan EK. Parkinson’s disease: Etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 2020;91(8):795-808. doi:10.1136/jnnp-2019-322338
- Kouli A, Torsney KM, Kuan WL. Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis. https://www.ncbi.nlm.nih.gov/books/NBK536722/ adresinden 22.05.2022 tarihinde erişilmiştir. doi:10.15586/codonpublications.parkinsonsdisease.2018.ch1
- Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Prim 2017;3:1-21. doi:10.1038/nrdp.2017.13
- Haehner A, Boesveldt S, Berendse HW, et al. Prevalence of smell loss in Parkinson’s disease – A multicenter study. Park Relat Disord 2009;15(7):490-4. doi:10.1016/j.parkreldis.2008.12.005
- Larsen JP, Tandberg E. Sleep disorders in patients with Parkinson’s disease: Epidemiology and management. CNS Drugs 2001;15(4):267-75. doi:10.2165/00023210-200115040-00002
- Knie B, Mitra MT, Logishetty K, Chaudhuri KR. Excessive daytime sleepiness in patients with parkinsons disease. CNS Drugs 2011;25(3):203-12. doi:10.2165/11539720-000000000-00000
- Monderer R, Thorpy M. Sleep disorders and daytime sleepiness in Parkinson’s disease. Curr Neurol Neurosci Rep 2009;9(2):173-80. doi:10.1007/s11910-009-0026-5
- Reijnders JSAM, Ehrt U, Weber WEJ, Aarsland D, Leentjens AFG. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 2008;23(2):183-9. doi:10.1002/mds.21803
- Schrag A, Jahanshahi M, Quinn NP. What contributes to depression in Parkinson’s disease? Psychol Med 2001;31(1):65-73. doi:10.1017/S0033291799003141
- Brown RG, Landau S, Hindle J V, et al. Depression and anxiety related subtypes in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2011;82(7):803-9. doi:10.1136/jnnp.2010.213652
- Pfeiffer RF. Gastrointestinal Dysfunction in Parkinson’s Disease. Curr Treat Options Neurol 2018;20(12):54. doi:10.1007/s11940-018-0539-9
- Jost WH, Augustis S. Severity of orthostatic hypotension in the course of Parkinson’s disease: No correlation with the duration of the disease. Park Relat Disord 2015;21(3):314-6. doi:10.1016/j.parkreldis.2014.12.016
- Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol 2009;8(12):1150-7. doi:10.1016/S1474-4422(09)70238-8
- Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson’s disease. Mov Disord 2011;26(6):1049-55. doi:10.1002/mds.23732
- Braak H, Del Tredici K, Rüb U, De Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24(2):197-211. doi:10.1016/S0197-4580(02)00065-9
- Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis. Neurology 2016;86(6):566-76. doi:10.1212/WNL.0000000000002350
- Brajkovic L, Kostic V, Sobic-Saranovic D, et al. The utility of FDG-PET in the differential diagnosis of Parkinsonism. Neurol Res 2017;39(8):675-84. doi:10.1080/01616412.2017.1312211
- Parnetti L, Gaetani L, Eusebi P, et al.CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol 2019;18(6):573-86. doi:10.1016/S1474-4422(19)30024-9
- Mak MK, Wong-Yu IS, Shen X, Chung CL.Long-term effects of exercise and physical therapy in people with Parkinson disease. Nat Rev Neurol 2017;13(11):689-703. doi:10.1038/NRNEUROL.2017.128
- Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 2018;33(8):1248-66. doi:10.1002/mds.27372
- Verschuur CVM, Suwijn SR, Boel JA, et al. Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease. N Engl J Med 2019;380(4):315-24. doi:10.1056/nejmoa1809983
- de Bie RMA, Clarke CE, Espay AJ, Fox SH, Lang AE. Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how. Lancet Neurol 2020;19(5):452-61. doi:10.1016/S1474-4422(20)30036-3
- Gray R, Ives N, Rick C, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): A large, open-label, pragmatic randomised trial. Lancet 2014;384(9949):1196-205. doi:10.1016/S0140-6736(14)60683-8
- Mitchell KT, Ostrem JL. Surgical Treatment of Parkinson Disease. Neurol Clin 2020;38(2):293-307. doi:10.1016/J.NCL.2020.01.001
- Fernandez HH, Boyd JT, Fung VSC, et al. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease. Mov Disord 2018;33(6):928-36. doi:10.1002/MDS.27338
- Marsili L, Bologna M, Miyasaki JM, Colosimo C. Parkinson’s disease advanced therapies – A systematic review: More unanswered questions than guidance. Parkinsonism RelatDisord 2021;83:132-9. doi:10.1016/j.parkreldis.2020.10.042
- Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2018;17(9):749-59. doi:10.1016/S1474-4422(18)30239-4
- Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiplesystem atrophy. Neurology 2008;71(9):670-6. doi:10.1212/01.WNL.0000324625.00404.15
- Krismer F, Wenning GK. Multiple system atrophy: insights into a rare and debilitating movement disorder. Nat Rev Neurol 2017;13(4):232-43. doi:10.1038/NRNEUROL.2017.26
- Trojanowski JQ, Revesz T, Neuropathology Working Group on MSA. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 2007;33(6):615-20. doi:10.1111/J.1365-2990.2007.00907.X
- Palma JA, Norcliffe-Kaufmann L, Kaufmann H. Diagnosis of multiple systematrophy. AutonNeurosci 2018;211:15-25. doi:10.1016/j.autneu.2017.10.007
- Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol 2010;23(4):394-400. doi:10.1097/WCO.0B013E32833BE924
- Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009;8(3):270-279. doi:10.1016/S1474-4422(09)70042-0
- Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord 2017;32(6):853-64. doi:10.1002/MDS.26987
- Sakurai K, Tokumaru AM, Shimoji K, et al. Beyond the midbrain atrophy: wide spectrum of structural MRI finding in cases of pathologically proven progressive supranuclear palsy. Neuroradiology 2017;59(5):431-43. doi:10.1007/S00234-017-1812-4
- Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol 2011;7(5):263-72. doi:10.1038/nrneurol.2011.43
- Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013;80(5):496. doi:10.1212/WNL.0B013E31827F0FD1
- Koyama M, Yagishita A, Nakata Y, Hayashi M, Bandoh M, Mizutani T. Imaging of corticobasal degeneration syndrome. Neuroradiology 2007;49(11):905-12. doi:10.1007/S00234-007-0265-6
- Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol 2012;8(1):15-21. doi:10.3988/JCN.2012.8.1.15.
